Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer

被引:17
作者
Evans, WK [1 ]
Earle, CC [1 ]
Stewart, DJ [1 ]
Dahrouge, S [1 ]
Tomiak, E [1 ]
Goss, G [1 ]
Logan, D [1 ]
Goel, R [1 ]
Gertler, SZ [1 ]
Dulude, H [1 ]
机构
[1] BRISTOL MYERS SQUIBB CANADA INC,ST LAURENT,PQ H4N 2M7,CANADA
关键词
non-small cell lung cancer; chemotherapy; paclitaxel; carboplatin;
D O I
10.1016/S0169-5002(97)00046-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the activity, toxicity, and optimal dose of paclitaxel when given by one hour infusion combined with carboplatin in advanced non-small cell lung cancer (NSCLC). Patients and Methods: Thirty-seven previously untreated patients with stage IIIB or IV NSCLC were enrolled. Paclitaxel was administered by one hour infusion at a dose of 175 mg/m(2) for the first cycle, and was escalated up to 225 mg/m(2) over successive cycles if tolerated. In the absence of toxicity, the carboplatin dose was kept constant at an area under the concentration-time curve (AUC) of 6. Cycles were repeated at 3-week intervals until progression or intolerable toxicity occurred. Results: Thirty-six patients were evaluable for toxicity and survival, and thirty-five for response. The partial response rate was 10 of 35 (29%) and there were no complete responses. The median duration of response was 4.8 months (range 0.5 - 11.7 months). The median survival duration was 6.5 months, and 1 year survival was 31%. The mean paclitaxel dose was 188 mg/m(2). Treatment was generally well tolerated. Four patients (11%) had febrile neutropenia. Five patients (14%) had grade 3 neuropathy, and 4 (11%) had grade 3 nausea and vomiting. Minor toxicities included alopecia, myalgias, arthralgias and stomatitis. Conclusions: Paclitaxel and carboplatin is a well-tolerated regimen that can safely be given by a one hour paclitaxel infusion. The modest response rate observed in this study may be due to either the low dose-intensity of paclitaxel or the short infusion duration. Further trials to optimize the relative doses of paclitaxel and carboplatin are needed. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:83 / 94
页数:12
相关论文
共 16 条
[1]  
BONOMI PD, 1990, CARBOPLATIN JM 8 CUR, P307
[2]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[3]  
CHANG AY, 1995, SEMIN ONCOL, V22, P124
[4]   PHASE-II STUDY OF TAXOL, MERBARONE, AND PIROXANTRONE IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - THE EASTERN COOPERATIVE ONCOLOGY GROUP RESULTS [J].
CHANG, AY ;
KIM, K ;
GLICK, J ;
ANDERSON, T ;
KARP, D ;
JOHNSON, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :388-394
[5]  
DEVITA VT, 1993, CANCER PRINCIPLES PR
[6]   EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION [J].
EISENHAUER, EA ;
HUININK, WWT ;
SWENERTON, KD ;
GIANNI, L ;
MYLES, J ;
VANDERBURG, MEL ;
KERR, I ;
VERMORKEN, JB ;
BUSER, K ;
COLOMBO, N ;
BACON, M ;
SANTABARBARA, P ;
ONETTO, N ;
WINOGRAD, B ;
CANETTA, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2654-2666
[7]  
GEORGIADIS MS, 1995, SEMIN ONCOL, V22, P67
[8]  
HAINSWORTH JD, 1996, P ASCO, P15
[9]   Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial [J].
Johnson, DH ;
Paul, DM ;
Hande, KR ;
Shyr, Y ;
Blanke, C ;
Murphy, B ;
Lewis, M ;
DeVore, RF .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :2054-2060
[10]  
JOHNSON DH, 1995, SEMIN ONCOL, V22, P30